{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:43:38Z","timestamp":1784641418613,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Rituximab (RTX) efficacy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been reported in large randomized studies; however, the efficacy of RTX in Japanese AAV patients, especially the elderly, is not well known. We aimed to determine the clinical efficacy of RTX in Japanese AAV patients including elderly patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 78 AAV patients newly diagnosed with AAV and treated in Fukushima Medical University Hospital or Ohta-Nishinouchi Hospital from April 2004 to September 2019. Clinical records were retrospectively reviewed, and clinical efficacy and outcome (1-year survival) between the RTX treatment group (23 cases) and the conventional therapy group (immunosuppressive therapy other than RTX, 55 cases) were compared. We also analysed the clinical efficacy and outcome in elderly-onset (&amp;gt;75\u2009years) AAV patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The RTX group showed similar efficacy and 1-year survival compared to the conventional therapy group. Conversely, after 6\u2009months of treatment, prednisolone doses significantly decreased in the RTX group compared to the conventional therapy group (p\u2009&amp;lt;\u20090.01). In the elderly-onset AAV patients, clinical efficacy and outcome were not significantly different.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RTX was effective in Japanese AAV patients and may be useful for prompt tapering of prednisolone doses, even in elderly-onset AAV patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/mr\/roac027","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:19:25Z","timestamp":1648559965000},"page":"352-359","source":"Crossref","is-referenced-by-count":7,"title":["Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: A two-centre study in Fukushima, Japan"],"prefix":"10.1093","volume":"33","author":[{"given":"Makiko","family":"Yashiro-Furuya","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-8261","authenticated-orcid":false,"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momo","family":"Akanuma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta-Nishinouchi Hospital , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta-Nishinouchi Hospital , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.60.2.170","article-title":"Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.1780351113","article-title":"The treatment of Wegener\u2019s granulomatosis with glucocorticoids and methotrexate","volume":"35","author":"Hoffman","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","article-title":"2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/s10165-011-0525-5","article-title":"Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study","volume":"22","author":"Ozaki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/ggi.13511","article-title":"Clinical features and outcomes in patients with elderly-onset anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"18","author":"Sato","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/14397595.2020.1790778","article-title":"Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan","volume":"31","author":"Takeyama","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1093\/ndt\/gfn354","article-title":"Renal vasculitis in Japan and the UK\u2014are there differences in epidemiology and clinical phenotype?","volume":"23","author":"Watts","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","DOI":"10.1186\/ar4550","article-title":"Research committee on intractable vasculitides, the ministry of health, labour and welfare of Japan. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"LoVAS collaborators. effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"Jama"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"Am J Nephrol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2023030304341276200_","first-page":"615","article-title":"Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment","volume":"37","author":"L\u00f3pez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1620\/tjem.242.53","article-title":"Remission induction therapy with rituximab for microscopic polyangiitis: a feasibility study","volume":"242","author":"Saito","year":"2017","journal-title":"Tohoku J Exp Med"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/rheumatology\/ket489","article-title":"Induction treatment of ANCA-associated vasculitis with a single dose of rituximab","volume":"53","author":"Turner-Stokes","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2014.918172","article-title":"Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients","volume":"43","author":"Moog","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","article-title":"Research committee on intractable vasculitides, the ministry of health, labour and welfare of Japan. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study","volume":"2","author":"Sada","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/14397595.2014.981945","article-title":"Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis","volume":"25","author":"Nagafuchi","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006083","article-title":"Spanish registry of systemic vasculitis (REVAS) from the Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity","volume":"96","author":"Solans-Laqu\u00e9","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/pgmj.72.849.423","article-title":"ANCA-associated vasculitis: diagnosis and treatment in the elderly","volume":"72","author":"Parry","year":"1996","journal-title":"Postgrad Med J"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Rahmattulla","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023030304341276200_","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac027\/43349481\/roac027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/352\/49400522\/roac027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/352\/49400522\/roac027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:02:10Z","timestamp":1700391730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/2\/352\/6554495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,26]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac027","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,3,26]]}}}